Joint Group Submission: House of Commons Standing Committee on Finance
Save Your Skin Foundation’s pre-budget recommendations call for faster access to cancer treatments, stronger research, and equitable care for all Canadians.
One of CIAN‘s key priorities is to advocate for equitable access to vaccines and therapeutics, inclusive policies, and a safer environment for immunocompromised people to live and thrive. To advance these efforts, we have undertaken several letter-writing campaigns directed to key policymakers and stakeholders within the provincial and federal governments.
By advancing these advocacy efforts with the united voice of our patient advocates and patient organizations, we ensure that Canada’s immunocompromised community is represented at decision-maker tables.
Save Your Skin Foundation’s pre-budget recommendations call for faster access to cancer treatments, stronger research, and equitable care for all Canadians.
CIAN submitted a letter to the Government of Alberta offering recommendations to strengthen support for immunocompromised individuals as part of the updated COVID-19 immunization program.
CIAN, in collaboration with CCRAN, Save Your Skin Foundation, and 14 other patient advocacy groups, welcomed Ontario’s announcement of a pilot program to accelerate access to high-priority cancer drugs—an important first step toward improving timely treatment.
CIAN, in collaboration with Lupus Ontario, is calling on the Ontario government to expand access to publicly funded RSV, shingles, and HPV vaccines for lupus patients and other immunocompromised individuals who face higher risks from these infections.
CIAN, as part of the Resilient Healthcare Coalition (RHC), is working alongside health system leaders to strengthen Canadian healthcare by improving data use and expanding access to innovative technologies like vaccines, diagnostics, and treatments.
Our letter to the Ontario Government expresses concern in the recent announcement to halt provincial wastewater monitoring of COVID-19 and other infectious diseases.
Our letter on protein-based COVID-19 vaccine options covers critical topics like access issues, awareness gaps, communication barriers, and skepticism.
Our letter to NACI expresses gratitude for their recent guidance regarding the use of COVID-19 vaccines for Fall 2024.